351 related articles for article (PubMed ID: 32562237)
1. Transcriptome Analysis of iPSC-Derived Neurons from Rubinstein-Taybi Patients Reveals Deficits in Neuronal Differentiation.
Calzari L; Barcella M; Alari V; Braga D; Muñoz-Viana R; Barlassina C; Finelli P; Gervasini C; Barco A; Russo S; Larizza L
Mol Neurobiol; 2020 Sep; 57(9):3685-3701. PubMed ID: 32562237
[TBL] [Abstract][Full Text] [Related]
2. iPSC-derived neurons of CREBBP- and EP300-mutated Rubinstein-Taybi syndrome patients show morphological alterations and hypoexcitability.
Alari V; Russo S; Terragni B; Ajmone PF; Sironi A; Catusi I; Calzari L; Concolino D; Marotta R; Milani D; Giardino D; Mantegazza M; Gervasini C; Finelli P; Larizza L
Stem Cell Res; 2018 Jul; 30():130-140. PubMed ID: 29883886
[TBL] [Abstract][Full Text] [Related]
3. Histone Deacetylase Inhibitors Ameliorate Morphological Defects and Hypoexcitability of iPSC-Neurons from Rubinstein-Taybi Patients.
Alari V; Scalmani P; Ajmone PF; Perego S; Avignone S; Catusi I; Lonati PA; Borghi MO; Finelli P; Terragni B; Mantegazza M; Russo S; Larizza L
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071322
[TBL] [Abstract][Full Text] [Related]
4. Genes for RNA-binding proteins involved in neural-specific functions and diseases are downregulated in Rubinstein-Taybi iNeurons.
Larizza L; Calzari L; Alari V; Russo S
Neural Regen Res; 2022 Jan; 17(1):5-14. PubMed ID: 34100419
[TBL] [Abstract][Full Text] [Related]
5. Rubinstein-Taybi Syndrome and Epigenetic Alterations.
Korzus E
Adv Exp Med Biol; 2017; 978():39-62. PubMed ID: 28523540
[TBL] [Abstract][Full Text] [Related]
6. Mutations in CREBBP and EP300 genes affect DNA repair of oxidative damage in Rubinstein-Taybi syndrome cells.
Dutto I; Scalera C; Tillhon M; Ticli G; Passaniti G; Cazzalini O; Savio M; Stivala LA; Gervasini C; Larizza L; Prosperi E
Carcinogenesis; 2020 May; 41(3):257-266. PubMed ID: 31504229
[TBL] [Abstract][Full Text] [Related]
7. Histone acetylation deficits in lymphoblastoid cell lines from patients with Rubinstein-Taybi syndrome.
Lopez-Atalaya JP; Gervasini C; Mottadelli F; Spena S; Piccione M; Scarano G; Selicorni A; Barco A; Larizza L
J Med Genet; 2012 Jan; 49(1):66-74. PubMed ID: 21984751
[TBL] [Abstract][Full Text] [Related]
8. Generation of the Rubinstein-Taybi syndrome type 2 patient-derived induced pluripotent stem cell line (IAIi001-A) carrying the EP300 exon 23 stop mutation c.3829A > T, p.(Lys1277*).
Alari V; Russo S; Rovina D; Gowran A; Garzo M; Crippa M; Mazzanti L; Scalera C; Prosperi E; Giardino D; Gervasini C; Finelli P; Pompilio G; Larizza L
Stem Cell Res; 2018 Jul; 30():175-179. PubMed ID: 29944992
[TBL] [Abstract][Full Text] [Related]
9. Rubinstein-Taybi 2 associated to novel EP300 mutations: deepening the clinical and genetic spectrum.
López M; García-Oguiza A; Armstrong J; García-Cobaleda I; García-Miñaur S; Santos-Simarro F; Seidel V; Domínguez-Garrido E
BMC Med Genet; 2018 Mar; 19(1):36. PubMed ID: 29506490
[TBL] [Abstract][Full Text] [Related]
10. Phenotype and genotype in 52 patients with Rubinstein-Taybi syndrome caused by EP300 mutations.
Fergelot P; Van Belzen M; Van Gils J; Afenjar A; Armour CM; Arveiler B; Beets L; Burglen L; Busa T; Collet M; Deforges J; de Vries BB; Dominguez Garrido E; Dorison N; Dupont J; Francannet C; Garciá-Minaúr S; Gabau Vila E; Gebre-Medhin S; Gener Querol B; Geneviève D; Gérard M; Gervasini CG; Goldenberg A; Josifova D; Lachlan K; Maas S; Maranda B; Moilanen JS; Nordgren A; Parent P; Rankin J; Reardon W; Rio M; Roume J; Shaw A; Smigiel R; Sojo A; Solomon B; Stembalska A; Stumpel C; Suarez F; Terhal P; Thomas S; Touraine R; Verloes A; Vincent-Delorme C; Wincent J; Peters DJ; Bartsch O; Larizza L; Lacombe D; Hennekam RC
Am J Med Genet A; 2016 Dec; 170(12):3069-3082. PubMed ID: 27648933
[TBL] [Abstract][Full Text] [Related]
11. Clinical and molecular characterization of Rubinstein-Taybi syndrome patients carrying distinct novel mutations of the EP300 gene.
Negri G; Milani D; Colapietro P; Forzano F; Della Monica M; Rusconi D; Consonni L; Caffi LG; Finelli P; Scarano G; Magnani C; Selicorni A; Spena S; Larizza L; Gervasini C
Clin Genet; 2015 Feb; 87(2):148-54. PubMed ID: 24476420
[TBL] [Abstract][Full Text] [Related]
12. CBP-HSF2 structural and functional interplay in Rubinstein-Taybi neurodevelopmental disorder.
de Thonel A; Ahlskog JK; Daupin K; Dubreuil V; Berthelet J; Chaput C; Pires G; Leonetti C; Abane R; Barris LC; Leray I; Aalto AL; Naceri S; Cordonnier M; Benasolo C; Sanial M; Duchateau A; Vihervaara A; Puustinen MC; Miozzo F; Fergelot P; Lebigot É; Verloes A; Gressens P; Lacombe D; Gobbo J; Garrido C; Westerheide SD; David L; Petitjean M; Taboureau O; Rodrigues-Lima F; Passemard S; Sabéran-Djoneidi D; Nguyen L; Lancaster M; Sistonen L; Mezger V
Nat Commun; 2022 Nov; 13(1):7002. PubMed ID: 36385105
[TBL] [Abstract][Full Text] [Related]
13. Case report: a Chinese girl like atypical Rubinstein-Taybi syndrome caused by a novel heterozygous mutation of the EP300 gene.
Bai Z; Li G; Kong X
BMC Med Genomics; 2023 Feb; 16(1):24. PubMed ID: 36797748
[TBL] [Abstract][Full Text] [Related]
14. Hyperinsulinism in an individual with an EP300 variant of Rubinstein-Taybi syndrome.
Wild KT; Nomakuchi TT; Sheppard SE; Leavens KF; De León DD; Zackai EH
Am J Med Genet A; 2021 Apr; 185(4):1251-1255. PubMed ID: 33442921
[TBL] [Abstract][Full Text] [Related]
15. From Whole Gene Deletion to Point Mutations of EP300-Positive Rubinstein-Taybi Patients: New Insights into the Mutational Spectrum and Peculiar Clinical Hallmarks.
Negri G; Magini P; Milani D; Colapietro P; Rusconi D; Scarano E; Bonati MT; Priolo M; Crippa M; Mazzanti L; Wischmeijer A; Tamburrino F; Pippucci T; Finelli P; Larizza L; Gervasini C
Hum Mutat; 2016 Feb; 37(2):175-83. PubMed ID: 26486927
[TBL] [Abstract][Full Text] [Related]
16. The transcriptional coactivator and histone acetyltransferase CBP regulates neural precursor cell development and migration.
Schoof M; Launspach M; Holdhof D; Nguyen L; Engel V; Filser S; Peters F; Immenschuh J; Hellwig M; Niesen J; Mall V; Ertl-Wagner B; Hagel C; Spohn M; Lutz B; Sedlacik J; Indenbirken D; Merk DJ; Schüller U
Acta Neuropathol Commun; 2019 Dec; 7(1):199. PubMed ID: 31806049
[TBL] [Abstract][Full Text] [Related]
17. A Novel CREBBP in-Frame Deletion Variant in a Chinese Girl with Atypical Rubinstein-Taybi Syndrome Phenotypes.
Wang Q; Xu W; Liu Y; Yuan H
J Mol Neurosci; 2021 Mar; 71(3):607-612. PubMed ID: 32839936
[TBL] [Abstract][Full Text] [Related]
18. Clinical and mutational spectrum in Korean patients with Rubinstein-Taybi syndrome: the spectrum of brain MRI abnormalities.
Lee JS; Byun CK; Kim H; Lim BC; Hwang H; Choi JE; Hwang YS; Seong MW; Park SS; Kim KJ; Chae JH
Brain Dev; 2015 Apr; 37(4):402-8. PubMed ID: 25108505
[TBL] [Abstract][Full Text] [Related]
19. De novo variation in EP300 gene cause Rubinstein-Taybi syndrome 2 in a Chinese family with severe early-onset high myopia.
Huang X; Rui X; Zhang S; Qi X; Rong W; Sheng X
BMC Med Genomics; 2023 Apr; 16(1):84. PubMed ID: 37085840
[TBL] [Abstract][Full Text] [Related]
20. Genetic heterogeneity in Rubinstein-Taybi syndrome: delineation of the phenotype of the first patients carrying mutations in EP300.
Bartholdi D; Roelfsema JH; Papadia F; Breuning MH; Niedrist D; Hennekam RC; Schinzel A; Peters DJ
J Med Genet; 2007 May; 44(5):327-33. PubMed ID: 17220215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
